Research programme: diabetes/obesity therapy - Devgen

Drug Profile

Research programme: diabetes/obesity therapy - Devgen

Alternative Names: Dev 0104

Latest Information Update: 10 Jul 2008

Price : $50

At a glance

  • Originator Devgen
  • Class
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2004 This programme is still in active development - (BioSquare-2004)
  • 10 Jul 2001 Preclinical development for Diabetes and Obesity in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top